GENE ONLINE|News &
Opinion
Blog

Trials & Approvals
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease
2025-04-15
Breaking New Ground in 2025 with 8 First-in-Class Drugs Close to FDA Approval – Part I
2025-03-31
Double Win With FDA’s Green Light Towards Two New Denosumab Biosimilars
2025-03-05
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
Eli Lilly’s Alzheimer’s Treatment Kisunla Secures Fourth Major Market Approval with NMPA Authorization in China
2024-12-18
Pfizer Pulls Sickle Cell Treatment Over Deadly Complication Risks
2024-09-26
Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another Autoimmune Treatment Avenue
2024-09-25
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
China Approves AstraZeneca’s Fasenra for Severe Eosinophilic Asthma
2024-08-21
FDA Greenlights First At-Home, Over-the-Counter Syphilis Diagnostic Test Amidst STD Increase
2024-08-21
Servier’s $1.8 Billion Acquisition Pays Off: FDA Approves First-In-Class Treatment for Two Types of Rare Brain Cancer
2024-08-07
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
Sanofi and Regeneron’s Dupixent Approved as First-in-World Treatment For Uncontrolled COPD
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
1 2 3 51
LATEST
Lupin Secures US FDA Tentative Approval for Oxcarbazepine ER Tablets Manufactured in Nagpur
2025-06-18
Investor Trust and Market Timing Shape the New IPO Playbook
2025-06-18
Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with Three Major Agreements Driving 59 Percent of M&A Value
2025-06-18
Eli Lilly Acquires SiteOne Therapeutics to Develop Non-Opioid Pain Treatment STC-004
2025-06-18
New Device Promises to Streamline CAR T-Cell Therapy Production for Earlier Cancer Treatment
2025-06-18
Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor
2025-06-18
Technological Advancements Reduce R&D Costs and Propel Growth of Cell and Gene Therapies in Biopharmaceutical Sector
2025-06-18
EVENT
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top